Terns Pharmaceuticals Inc (TERN)

Merck & Co. has surged past the S&P 500 Index over the past year, and analysts remain somewhat optimistic about the stock’s growth potential.

Addition of TERN-701, a novel investigational oral allosteric BCR::ABL1 tyrosine kinase inhibitor, further diversifies Merck’s oncology pipeline

Merck & Co. has outperformed the broader market over the past year, and analysts remain moderately optimistic about the stock’s prospects.

FOSTER CITY, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage oncology company, today announced that the U.S....

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (“HSR”),...

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti , LLC (“KSF”) are investigating the proposed sale of Terns Pharmaceuticals...

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.

Merck & Co. is expected to unveil its first-quarter results later this month, and analysts are projecting a triple-digit decline in profit.

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, is commencing today, through a subsidiary, a cash tender offer to purchase all outstanding shares of common stock of Terns Pharmaceuticals,...